The goal for the treatment of patients with diabetes has today shifted from merely reducing glucose concentrations to preventing the natural decline in β-cell function and delay the progression of disease. Pancreatic β-cell dysfunction and decreased β-cell mass are crucial in the development of diabetes. The β-cell defects are the main pathogenesis in patients with type 1 diabetes and are associated with type 2 diabetes as the disease progresses. Recent studies suggest that human pancreatic β-cells have a capacity for increased proliferation according to increased demands for insulin. In humans, β-cell mass has been shown to increase in patients showing insulin-resistance states such as obesity or in pregnancy. This capacity might be useful for identifying new therapeutic strategies to reestablish a functional β-cell mass. In this context, therapeutic approaches designed to increase β-cell mass might prove a significant way to manage diabetes and prevent its progression. This review describes the various β-cell defects that appear in patients with diabetes and outline the mechanisms of β-cell failure. We also review common methods for assessing β-cell function and mass and methodological limitations in vivo. Finally, we discuss the current therapeutic approaches to improve β-cell function and increase β-cell mass.

Citations

Citations to this article as recorded by  

• Polychlorinated biphenyls exposure and type 2 diabetes: Molecular mechanism that causes insulin resistance and islet damage
  Qiuli Shan, Jingyu Liu, Fan Qu, Anhui Chen, Wenxing He
  Environmental Toxicology.2024; 39(4): 2466.     CrossRef
• Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
  Laure Sayyed Kassem, Aman Rajpal, Margarita Victoria Barreiro, Faramarz Ismail‐Beigi
  Journal of Diabetes.2023; 15(10): 817.     CrossRef
• Preliminary Evaluation of Potential Properties of Three Probiotics and Their Combination with Prebiotics on GLP-1 Secretion and Type 2 Diabetes Alleviation
  Ran Xiao, Ran Wang, Shusen Li, Xiaohong Kang, Yimei Ren, Erna Sun, Chenyuan Wang, Jingjing He, Jing Zhan, Wen Yi Kang
  Journal of Food Quality.2022; 2022: 1.     CrossRef
• Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements
  Muhammad Fauzi, Takaaki Murakami, Hiroyuki Fujimoto, Ainur Botagarova, Kentaro Sakaki, Sakura Kiyobayashi, Masahito Ogura, Nobuya Inagaki
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
  Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
  Phytomedicine.2019; 62: 152946.     CrossRef
• The Potential of Hibiscus sabdariffa Linn in Inducing Glucagon-Like Peptide-1 via SGLT-1 and GLPR in DM Rats
  Neng Tine Kartinah, Fadilah Fadilah, Ermita Ilyas Ibrahim, Yuliana Suryati
  BioMed Research International.2019; 2019: 1.     CrossRef
• Efficacy of short‑term intensive treatment with insulin pump to improve islet β‑cell function in newly diagnosed type 2 diabetes via inhibition of oxidative stress
  Hai‑Tong Liu, Yan Gao
  Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
• When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
  Angelo Avogaro, Elías Delgado, Ildiko Lingvay
  Diabetes/Metabolism Research and Reviews.2018;[Epub]     CrossRef
• Metformin prevents glucotoxicity by alleviating oxidative and ER stress–induced CD36 expression in pancreatic beta cells
  Jun Sung Moon, Udayakumar Karunakaran, Suma Elumalai, In-Kyu Lee, Hyoung Woo Lee, Yong-Woon Kim, Kyu Chang Won
  Journal of Diabetes and its Complications.2017; 31(1): 21.     CrossRef
• The variability in beta‐cell function in placebo‐treated subjects with type 2 diabetes: application of the weight‐HbA1c‐insulin‐glucose (WHIG) model
  Janna K. Duong, Willem de Winter, Steve Choy, Nele Plock, Himanshu Naik, Walter Krauwinkel, Sandra A.G. Visser, Katia M. Verhamme, Miriam C. Sturkenboom, B.H. Stricker, Meindert Danhof
  British Journal of Clinical Pharmacology.2017; 83(3): 487.     CrossRef
• Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling
  Bethany A. Carboneau, Richard M. Breyer, Maureen Gannon
  Journal of Cell Communication and Signaling.2017; 11(2): 105.     CrossRef
• Effects of low intensity laser acupoint irradiation on inhibiting islet beta-cell apoptosis in rats with type 2 diabetes
  Guoxin Xiong, Leilei Xiong, Xinzhong Li
  Laser Physics.2016; 26(9): 095605.     CrossRef
• Effects of continuous positive airway pressure treatment on glucose metabolism in patients with obstructive sleep apnea
  Elisabet Martínez-Ceron, Isabel Fernández-Navarro, Francisco Garcia-Rio
  Sleep Medicine Reviews.2016; 25: 121.     CrossRef
• Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase III trial
  S. Hong, C.‐Y. Park, K. A. Han, C. H. Chung, B. J. Ku, H. C. Jang, C. W. Ahn, M.‐K. Lee, M. K. Moon, H. S. Son, C. B. Lee, Y.‐W. Cho, S.‐W. Park
  Diabetes, Obesity and Metabolism.2016; 18(5): 528.     CrossRef
• Senp2 expression was induced by chronic glucose stimulation in INS1 cells, and it was required for the associated induction of Ccnd1 and Mafa
  Hye Seung Jung, Yu Mi Kang, Ho Seon Park, Byung Yong Ahn, Hakmo Lee, Min Joo Kim, Jin Young Jang, Sun-Whe Kim
  Islets.2016; 8(6): 207.     CrossRef
• ANTIDIABETIC EVALUATION OF CHONEMORPHA MACROPHYLLA ROOTS BY IN VIVO METHODS USING MALE WISTAR ALBINO RATS AND ITS MECHANISM OF ACTION
  K. R. Krishna Kumar, K. K. Srinivasan
  INDIAN DRUGS.2016; 53(12): 42.     CrossRef
• Comparative gene expression profiles in pancreatic islets associated with agouti yellow mutation and PACAP overexpression in mice
  Kazuya Ikeda, Shuhei Tomimoto, Soken Tsuchiya, Ken-ichi Hamagami, Norihito Shintani, Yukihiko Sugimoto, Atsushi Ichikawa, Atsushi Kasai, Takanobu Nakazawa, Kazuki Nagayasu, Atsuko Hayata-Takano, Akemichi Baba, Hitoshi Hashimoto
  Biochemistry and Biophysics Reports.2015; 2: 179.     CrossRef
• Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes
  LI-XUE GUAN, HUI GUAN, HAI-BO LI, CUI-AI REN, LIN LIU, JIN-JIN CHU, LONG-JUN DAI
  Experimental and Therapeutic Medicine.2015; 9(5): 1623.     CrossRef
• p13 overexpression in pancreatic β-cells ameliorates type 2 diabetes in high-fat-fed mice
  Shintaro Higashi, Kazuhiko Katagi, Norihito Shintani, Kazuya Ikeda, Yukihiko Sugimoto, Soken Tsuchiya, Naoki Inoue, Shota Tanaka, Mai Koumoto, Atsushi Kasai, Takanobu Nakazawa, Atsuko Hayata-Takano, Ken-Ichi Hamagami, Shuhei Tomimoto, Takuya Yoshida, Tada
  Biochemical and Biophysical Research Communications.2015; 461(4): 612.     CrossRef